1. Home
  2. QFIN vs SYRE Comparison

QFIN vs SYRE Comparison

Compare QFIN & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qifu Technology Inc.

QFIN

Qifu Technology Inc.

HOLD

Current Price

$19.67

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$31.59

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QFIN
SYRE
Founded
2016
2013
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.6B
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
QFIN
SYRE
Price
$19.67
$31.59
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$36.85
$56.50
AVG Volume (30 Days)
2.0M
888.4K
Earning Date
11-18-2025
11-04-2025
Dividend Yield
7.80%
N/A
EPS Growth
40.93
N/A
EPS
6.93
N/A
Revenue
$2,752,357,572.00
N/A
Revenue This Year
$16.96
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.81
N/A
Revenue Growth
14.06
N/A
52 Week Low
$17.61
$10.91
52 Week High
$48.94
$35.31

Technical Indicators

Market Signals
Indicator
QFIN
SYRE
Relative Strength Index (RSI) 46.60 52.33
Support Level $18.80 $32.50
Resistance Level $20.10 $33.22
Average True Range (ATR) 0.70 1.40
MACD 0.23 -0.56
Stochastic Oscillator 60.69 2.76

Price Performance

Historical Comparison
QFIN
SYRE

About QFIN Qifu Technology Inc.

Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: